Vascular inflammation is a missing link for Diabetes-enhanced atherosclerotic cardiovascular diseases

Frontiers in Bioscience

Volumn 17, Issue 3, 2012, Pages 1140-1164

  Shirwany, Najeeb A ^a   Zou, Ming Hui ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Atheroslcerosis; Cardiovascular disease; Diabetes; Review; Vascular inflammation

Indexed keywords

AUTACOID;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HUMAN; METABOLISM; VASCULITIS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; INFLAMMATION MEDIATORS; VASCULITIS;

EID: 84859258186     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3978     Document Type: Article

References (213)

1. A. R. Brasier, A. Recinos 3rd and M. S. Eledrisi: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol, 22(8), 1257-66 (2002). (Pubitemid 34875734)
2. R. Ross: Atherosclerosis-an inflammatory disease. N Engl J Med, 340(2), 115-26 (1999).
3. D. F. van Wijk and S. M. Boekholdt: Improving risk stratification for cardiovascular disease. Expert Rev Cardiovasc Ther, 8(8), 1091-3 (2010).
4. P. Libby, P. M. Ridker and G. K. Hansson: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol, 54(23), 2129-38 (2009).
5. T. Munzel and T. Gori: Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur Heart J, 30(23), 2829-31 (2009).
6. D. De Keyzer, S. A. Karabina, W. Wei, B. Geeraert, D. Stengel, J. Marsillach, J. Camps, P. Holvoet and E. Ninio: Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol, 29(12), 2041-6 (2009).
7. P. M. Ridker, E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson and R. J. Glynn: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 359(21), 2195-207 (2008).
8. G. Biasillo, M. Leo, R. Della Bona and L. M. Biasucci: Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med, 5(3), 225-33 (2010).
9. C. W. Hamm, C. Heeschen, B. Goldmann, A. Vahanian, J. Adgey, C. M. Miguel, W. Rutsch, J. Berger, J. Kootstra and M. L. Simoons: Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med, 340(21), 1623-9 (1999). (Pubitemid 29249431)
10. J. R. Lee, J. K. Kim, S. J. Lee and K. P. Kim: Role of protein tyrosine nitration in neurodegenerative diseases and atherosclerosis. Arch Pharm Res, 32(8), 1109-18 (2009).
11. L. Zheng, B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, H. Ischiropoulos, J. D. Smith, M. Kinter and S. L. Hazen: Apolipoprotein A-I is a selective target for myeloperoxidasecatalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest, 114(4), 529-41 (2004). (Pubitemid 39572103)
12. H. C. Stary, A. B. Chandler, S. Glagov, J. R. Guyton, W. Insull Jr., M. E. Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. Wagner and R. W. Wissler: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 89(5), 2462-78 (1994). (Pubitemid 24142837)
13. A. J. Merched, K. Ko, K. H. Gotlinger, C. N. Serhan and L. Chan: Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J, 22(10), 3595-606 (2008).
14. Y. Zhang, W. J. Cliff, G. I. Schoefl and G. Higgins: Plasma protein insudation as an index of early coronary atherogenesis. Am J Pathol, 143(2), 496-506 (1993). (Pubitemid 24058205)
15. H. Loppnow, K. Werdan and M. Buerke: Vascular cells contribute to atherosclerosis by cytokine- and innateimmunity- related inflammatory mechanisms. Innate Immun, 14(2), 63-87 (2008).
16. G. K. Hansson and P. Libby: The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 6(7), 508-19 (2006). (Pubitemid 43980523)
17. P. Libby: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr, 83(2), 456S-460S (2006).
18. R. De Caterina: Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care, 3(6), 453-67 (2000).
19. C. D. Stehouwer, J. Lambert, A. J. Donker and V. W. van Hinsbergh: Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res, 34(1), 55-68 (1997). (Pubitemid 27261913)
20. T. Mazzone: Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data. Circulation, 122(21), 2201-11 (2010).
21. M. Y. Donath and S. E. Shoelson: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol (2011).
22. C. M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J. Ehses, B. Seifert, T. Mandrup-Poulsen and M. Donath: [Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]. Ugeskr Laeger, 169(45), 3868-71 (2007).
23. A. Fleischman, S. E. Shoelson, R. Bernier and A. B. Goldfine: Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care, 31(2), 289-94 (2008). (Pubitemid 351213338)
24. H. Dominguez, H. Storgaard, C. Rask-Madsen, T. Steffen Hermann, N. Ihlemann, D. Baunbjerg Nielsen, C. Spohr, L. Kober, A. Vaag and C. Torp-Pedersen: Metabolic and vascular effects of tumor necrosis factoralpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res, 42(6), 517-25 (2005). (Pubitemid 41527607)
25. J. Lo, L. E. Bernstein, B. Canavan, M. Torriani, M. B. Jackson, R. S. Ahima and S. K. Grinspoon: Effects of TNFalpha neutralization on adipocytokines and skeletal muscleadiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab, 293(1), E102-9 (2007). (Pubitemid 47105923)
26. D. Brealey and M. Singer: Hyperglycemia in critical illness: a review. J Diabetes Sci Technol, 3(6), 1250-60 (2009).
27. S. S. Korshunov, V. P. Skulachev and A. A. Starkov: High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett, 416(1), 15-8 (1997). (Pubitemid 27470791)
28. S. Dhindsa, D. Tripathy, P. Mohanty, H. Ghanim, T. Syed, A. Aljada and P. Dandona: Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factor-kappaB in mononuclear cells. Metabolism, 53(3), 330-4 (2004). (Pubitemid 38684693)
29. A. Aljada, J. Friedman, H. Ghanim, P. Mohanty, D. Hofmeyer, A. Chaudhuri and P. Dandona: Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism, 55(9), 1177-85 (2006). (Pubitemid 44215936)
30. L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J. P. Cristol and C. Colette: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA, 295(14), 1681-7 (2006).
31. A. Jacob, M. L. Steinberg, J. Yang, W. Dong, Y. Ji and P. Wang: Sepsis-induced inflammation is exacerbated in an animal model of type 2 diabetes. Int J Clin Exp Med, 1(1), 22-31 (2008).
32. M. R. Dasu, S. Devaraj and I. Jialal: High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab, 293(1), E337-46 (2007). (Pubitemid 47105949)
33. G. Boden and X. Chen: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest, 96(3), 1261-8 (1995).
34. G. Boden, B. Lebed, M. Schatz, C. Homko and S. Lemieux: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes, 50(7), 1612-7 (2001). (Pubitemid 33639602)
35. S. I. Itani, N. B. Ruderman, F. Schmieder and G. Boden: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes, 51(7), 2005-11 (2002). (Pubitemid 34729001)
36. G. Boden, P. She, M. Mozzoli, P. Cheung, K. Gumireddy, P. Reddy, X. Xiang, Z. Luo and N. Ruderman: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes, 54(12), 3458-65 (2005). (Pubitemid 43334336)
37. C. Yu, Y. Chen, G. W. Cline, D. Zhang, H. Zong, Y. Wang, R. Bergeron, J. K. Kim, S. W. Cushman, G. J. Cooney, B. Atcheson, M. F. White, E. W. Kraegen and G. I. Shulman: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem, 277(52), 50230-6 (2002). (Pubitemid 36042170)
38. L. Chang, S. H. Chiang and A. R. Saltiel: Insulin signaling and the regulation of glucose transport. Mol Med, 10(7-12), 65-71 (2004). (Pubitemid 41825486)
39. T. Inoguchi, P. Li, F. Umeda, H. Y. Yu, M. Kakimoto, M. Imamura, T. Aoki, T. Etoh, T. Hashimoto, M. Naruse, H. Sano, H. Utsumi and H. Nawata: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49(11), 1939-45 (2000).
40. O. A. MacDougald and C. F. Burant: The rapidly expanding family of adipokines. Cell Metab, 6(3), 159-61 (2007). (Pubitemid 47324145)
41. H. Zhang, J. Cui and C. Zhang: Emerging role of adipokines as mediators in atherosclerosis. World J Cardiol, 2(11), 370-6 (2010).
42. D. E. Moller and K. D. Kaufman: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med, 56, 45-62 (2005). (Pubitemid 40299773)
43. J. E. Manson, G. A. Colditz, M. J. Stampfer, W. C. Willett, B. Rosner, R. R. Monson, F. E. Speizer and C. H. Hennekens: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med, 322(13), 882-9 (1990). (Pubitemid 20108377)
44. G. S. Hotamisligil: Inflammation and metabolic disorders. Nature, 444(7121), 860-7 (2006). (Pubitemid 46024993)
45. V. Z. Rocha, E. J. Folco, G. Sukhova, K. Shimizu, I. Gotsman, A. H. Vernon and P. Libby: Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res, 103(5), 467-76 (2008).
46. H. Wu, S. Ghosh, X. D. Perrard, L. Feng, G. E. Garcia, J. L. Perrard, J. F. Sweeney, L. E. Peterson, L. Chan, C. W. Smith and C. M. Ballantyne: T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation, 115(8), 1029-38 (2007). (Pubitemid 46328297)
47. C. Lohmann, N. Schafer, T. von Lukowicz, M. A. Sokrates Stein, J. Boren, S. Rutti, W. Wahli, M. Y. Donath, T. F. Luscher and C. M. Matter: Atherosclerotic mice exhibit systemic inflammation in periadventitial and visceral adipose tissue, liver, and pancreatic islets. Atherosclerosis, 207(2), 360-7 (2009).
48. N. Ouchi, S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, S. Yamashita, T. Funahashi and Y. Matsuzawa: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100(25), 2473-6 (1999). (Pubitemid 30005109)
49. Y. Arita, S. Kihara, N. Ouchi, K. Maeda, H. Kuriyama, Y. Okamoto, M. Kumada, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, I. Shimomura, M. Muraguchi, Y. Ohmoto, T. Funahashi and Y. Matsuzawa: Adipocytederived plasma protein adiponectin acts as a plateletderived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 105(24), 2893-8 (2002). (Pubitemid 34666104)
50. N. Ouchi, S. Kihara, Y. Arita, M. Nishida, A. Matsuyama, Y. Okamoto, M. Ishigami, H. Kuriyama, K. Kishida, H. Nishizawa, K. Hotta, M. Muraguchi, Y. Ohmoto, S. Yamashita, T. Funahashi and Y. Matsuzawa: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 103(8), 1057-63 (2001). (Pubitemid 32200177)
51. L. Tian, N. Luo, R. L. Klein, B. H. Chung, W. T. Garvey and Y. Fu: Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis, 202(1), 152-61 (2009).
52. K. Tsubakio-Yamamoto, F. Matsuura, M. Koseki, H. Oku, J. C. Sandoval, M. Inagaki, K. Nakatani, H. Nakaoka, R. Kawase, M. Yuasa-Kawase, D. Masuda, T. Ohama, N. Maeda, Y. Nakagawa-Toyama, M. Ishigami, M. Nishida, S. Kihara, I. Shimomura and S. Yamashita: Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun, 375(3), 390-4 (2008).
53. Y. Okamoto, E. J. Folco, M. Minami, A. K. Wara, M. W. Feinberg, G. K. Sukhova, R. A. Colvin, S. Kihara, T. Funahashi, A. D. Luster and P. Libby: Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res, 102(2), 218-25 (2008). (Pubitemid 351651126)
54. X. J. Cai, L. Chen, L. Li, M. Feng, X. Li, K. Zhang, Y. Y. Rong, X. B. Hu, M. X. Zhang, Y. Zhang and M. Zhang: Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol Endocrinol, 24(1), 218-28 (2010).
55. N. Luo, J. Liu, B. H. Chung, Q. Yang, R. L. Klein, W. T. Garvey and Y. Fu: Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes, 59(4), 791-9 (2010).
56. Y. Okamoto, S. Kihara, N. Ouchi, M. Nishida, Y. Arita, M. Kumada, K. Ohashi, N. Sakai, I. Shimomura, H. Kobayashi, N. Terasaka, T. Inaba, T. Funahashi and Y. Matsuzawa: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 106(22), 2767-70 (2002). (Pubitemid 35396973)
57. M. Zeadin, M. Butcher, G. Werstuck, M. Khan, C. K. Yee and S. G. Shaughnessy: Effect of leptin on vascular calcification in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 29(12), 2069-75 (2009).
58. P. F. Bodary, S. Gu, Y. Shen, A. H. Hasty, J. M. Buckler and D. T. Eitzman: Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 25(8), e119-22 (2005).
59. S. Taleb, O. Herbin, H. Ait-Oufella, W. Verreth, P. Gourdy, V. Barateau, R. Merval, B. Esposito, K. Clement, P. Holvoet, A. Tedgui and Z. Mallat: Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol, 27(12), 2691-8 (2007). (Pubitemid 350158924)
60. R. Z. Yang, Q. Huang, A. Xu, J. C. McLenithan, J. A. Eisen, A. R. Shuldiner, S. Alkan and D. W. Gong: Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun, 310(3), 927-35 (2003). (Pubitemid 37188711)
61. A. Fukuhara, M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, K. Kishimoto, Y. Matsuki, M. Murakami, T. Ichisaka, H. Murakami, E. Watanabe, T. Takagi, M. Akiyoshi, T. Ohtsubo, S. Kihara, S. Yamashita, M. Makishima, T. Funahashi, S. Yamanaka, R. Hiramatsu, Y. Matsuzawa and I. Shimomura: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307(5708), 426-30 (2005). (Pubitemid 40139988)
62. A. R. Moschen, A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, H. Niederegger and H. Tilg: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol, 178(3), 1748-58 (2007). (Pubitemid 46154646)
63. M. Brownlee: Advanced protein glycosylation in diabetes and aging. Annu Rev Med, 46, 223-34 (1995).
64. E. D. Schleicher, E. Wagner and A. G. Nerlich: Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest, 99(3), 457-68 (1997). (Pubitemid 27414803)
65. M. U. Ahmed, E. Brinkmann Frye, T. P. Degenhardt, S. R. Thorpe and J. W. Baynes: N-epsilon- (carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J, 324 ( Pt 2), 565-70 (1997).
66. S. Miyata and V. Monnier: Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest, 89(4), 1102-12 (1992).
67. K. Ienaga, K. Nakamura, T. Hochi, Y. Nakazawa, Y. Fukunaga, H. Kakita and K. Nakano: Crosslines, fluorophores in the AGE-related cross-linked proteins. Contrib Nephrol, 112, 42-51 (1995).
68. S. Tanaka, G. Avigad, B. Brodsky and E. F. Eikenberry: Glycation induces expansion of the molecular packing of collagen. J Mol Biol, 203(2), 495-505 (1988).
69. R. Bucala, K. J. Tracey and A. Cerami: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest, 87(2), 432-8 (1991).
70. J. el Khoury, C. A. Thomas, J. D. Loike, S. E. Hickman, L. Cao and S. C. Silverstein: Macrophages adhere to glucosemodified basement membrane collagen IV via their scavenger receptors. J Biol Chem, 269(14), 10197-200 (1994). (Pubitemid 24198204)
71. T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan, M. Hofmann, S. F. Yan, M. Pischetsrieder, D. Stern and A. M. Schmidt: N(epsilon)- (carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem, 274(44), 31740-9 (1999).
72. S. F. Yan, R. Ramasamy, Y. Naka and A. M. Schmidt: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res, 93(12), 1159-69 (2003). (Pubitemid 37543056)
73. A. Chait and K. E. Bornfeldt: Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res, 50 Suppl, S335- 9 (2009).
74. R. G. Gerrity, R. Natarajan, J. L. Nadler and T. Kimsey: Diabetes-induced accelerated atherosclerosis in swine. Diabetes, 50(7), 1654-65 (2001). (Pubitemid 33639607)
75. L. Park, K. G. Raman, K. J. Lee, Y. Lu, L. J. Ferran, Jr., W. S. Chow, D. Stern and A. M. Schmidt: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med, 4(9), 1025- 31 (1998). (Pubitemid 28417334)
76. P. Reaven, S. Merat, F. Casanada, M. Sutphin and W. Palinski: Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol, 17(10), 2250-6 (1997). (Pubitemid 28057129)
77. C. B. Renard, F. Kramer, F. Johansson, N. Lamharzi, L. R. Tannock, M. G. von Herrath, A. Chait and K. E. Bornfeldt: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest, 114(5), 659-68 (2004). (Pubitemid 39578756)
78. R. K. Vikramadithyan, Y. Hu, H. L. Noh, C. P. Liang, K. Hallam, A. R. Tall, R. Ramasamy and I. J. Goldberg: Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest, 115(9), 2434-43 (2005). (Pubitemid 41266205)
79. S. M. Haffner, M. P. Stern, H. P. Hazuda, B. D. Mitchell and J. K. Patterson: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA, 263(21), 2893-8 (1990).
80. K. Choi and Y. B. Kim: Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med, 25(2), 119-29 (2010).
81. L. Duvnjak and M. Duvnjak: The metabolic syndrome - an ongoing story. J Physiol Pharmacol, 60 Suppl 7, 19-24 (2009).
82. R. A. DeFronzo: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia, 53(7), 1270-87 (2010).
83. G. S. Hotamisligil, N. S. Shargill and B. M. Spiegelman: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 259(5091), 87-91 (1993). (Pubitemid 23036092)
84. K. T. Uysal, S. M. Wiesbrock, M. W. Marino and G. S. Hotamisligil: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 389(6651), 610-4 (1997). (Pubitemid 27446179)
85. F. Ofei, S. Hurel, J. Newkirk, M. Sopwith and R. Taylor: Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes, 45(7), 881-5 (1996). (Pubitemid 26225502)
86. J. K. Kim, Y. J. Kim, J. J. Fillmore, Y. Chen, I. Moore, J. Lee, M. Yuan, Z. W. Li, M. Karin, P. Perret, S. E. Shoelson and G. I. Shulman: Prevention of fatinduced insulin resistance by salicylate. J Clin Invest, 108(3), 437-46 (2001). (Pubitemid 32730790)
87. J. Hirosumi, G. Tuncman, L. Chang, C. Z. Gorgun, K. T. Uysal, K. Maeda, M. Karin and G. S. Hotamisligil: A central role for JNK in obesity and insulin resistance. Nature, 420(6913), 333-6 (2002). (Pubitemid 35398190)
88. K. Ueki, T. Kondo and C. R. Kahn: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol, 24(12), 5434-46 (2004). (Pubitemid 38738176)
89. D. B. Savage, K. F. Petersen and G. I. Shulman: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension, 45(5), 828-33 (2005). (Pubitemid 40628921)
90. R. Ross: Atherosclerosis is an inflammatory disease. Am Heart J, 138(5 Pt 2), S419-20 (1999). (Pubitemid 29523224)
91. G. Stoll and M. Bendszus: Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 37(7), 1923-32 (2006). (Pubitemid 44297753)
92. J. Davignon and P. Ganz: Role of endothelial dysfunction in atherosclerosis. Circulation, 109(23 Suppl 1), III27-32 (2004). (Pubitemid 38786440)
93. H. F. Langer and T. Chavakis: Leukocyte-endothelial interactions in inflammation. J Cell Mol Med, 13(7), 1211-20 (2009).
94. P. Dandona, A. Aljada and A. Bandyopadhyay: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol, 25(1), 4-7 (2004). (Pubitemid 38032801)
95. M. A. Crook, P. Tutt and J. C. Pickup: Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care, 16(1), 57-60 (1993). (Pubitemid 23013825)
96. J. C. Pickup, M. B. Mattock, G. D. Chusney and D. Burt: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 40(11), 1286-92 (1997). (Pubitemid 27469668)
97. M. I. Schmidt, B. B. Duncan, A. R. Sharrett, G. Lindberg, P. J. Savage, S. Offenbacher, M. I. Azambuja, R. P. Tracy and G. Heiss: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet, 353(9165), 1649-52 (1999). (Pubitemid 29224520)
98. A. Kubaszek, J. Pihlajamaki, V. Komarovski, V. Lindi, J. Lindstrom, J. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne- Parikka, S. Keinanen-Kiukaanniemi, J. Tuomilehto, M. Uusitupa and M. Laakso: Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes, 52(7), 1872-6 (2003). (Pubitemid 36792481)
99. A. Kubaszek, J. Pihlajamaki, P. Karhapaa, I. Vauhkonen and M. Laakso: The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care, 26(2), 464-7 (2003). (Pubitemid 36929074)
100. A. Kubaszek, J. Pihlajamaki, K. Punnonen, P. Karhapaa, I. Vauhkonen and M. Laakso: The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes, 52(2), 558-61 (2003). (Pubitemid 36173216)
101. R. K. Mathur: Role of diabetes, hypertension, and cigarette smoking on atherosclerosis. J Cardiovasc Dis Res, 1(2), 64-8 (2010).
102. V. V. Kunjathoor, D. L. Wilson and R. C. LeBoeuf: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest, 97(7), 1767-73 (1996). (Pubitemid 26105486)
103. M. R. Sartippour, A. Lambert, M. Laframboise, P. St- Jacques and G. Renier: Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes, 47(3), 431-8 (1998). (Pubitemid 28104206)
104. G. Booth, T. J. Stalker, A. M. Lefer and R. Scalia: Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol Endocrinol Metab, 280(6), E848-56 (2001).
105. J. F. Keaney Jr., J. M. Massaro, M. G. Larson, R. S. Vasan, P. W. Wilson, I. Lipinska, D. Corey, P. Sutherland, J. A. Vita and E. J. Benjamin: Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. J Am Coll Cardiol, 44(1), 168-73 (2004). (Pubitemid 38968477)
106. A. Festa, R. D'Agostino, Jr., G. Howard, L. Mykkanen, R. P. Tracy and S. M. Haffner: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102(1), 42-7 (2000). (Pubitemid 30430551)
107. M. B. Schulze, E. B. Rimm, T. Li, N. Rifai, M. J. Stampfer and F. B. Hu: C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care, 27(4), 889-94 (2004). (Pubitemid 38420210)
108. S. E. Shoelson, J. Lee and A. B. Goldfine: Inflammation and insulin resistance. J Clin Invest, 116(7), 1793-801 (2006). (Pubitemid 44033299)
109. F. Kim, B. Gallis and M. A. Corson: TNF-alpha inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am J Physiol Cell Physiol, 280(5), C1057-65 (2001).
110. A. Bierhaus, T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H. Tritschler, P. Wahl, R. Ziegler, M. Muller and P. P. Nawroth: Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation, 96(7), 2262-71 (1997). (Pubitemid 27425832)
111. A. Bierhaus, S. Chevion, M. Chevion, M. Hofmann, P. Quehenberger, T. Illmer, T. Luther, E. Berentshtein, H. Tritschler, M. Muller, P. Wahl, R. Ziegler and P. P. Nawroth: Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 46(9), 1481-90 (1997). (Pubitemid 27369087)
112. C. de Alvaro, T. Teruel, R. Hernandez and M. Lorenzo: Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem, 279(17), 17070-8 (2004). (Pubitemid 38560462)
113. F. Kim, K. A. Tysseling, J. Rice, M. Pham, L. Haji, B. M. Gallis, A. S. Baas, P. Paramsothy, C. M. Giachelli, M. A. Corson and E. W. Raines: Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol, 25(5), 989-94 (2005). (Pubitemid 40627844)
114. A. J. Donato, I. Eskurza, A. E. Silver, A. S. Levy, G. L. Pierce, P. E. Gates and D. R. Seals: Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB. Circ Res, 100(11), 1659-66 (2007). (Pubitemid 46897269)
115. T. Inoguchi, R. Battan, E. Handler, J. R. Sportsman, W. Heath and G. L. King: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA, 89(22), 11059-63 (1992).
116. B. Tesfamariam, M. L. Brown and R. A. Cohen: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest, 87(5), 1643-8 (1991).
117. C. Rask-Madsen and G. L. King: Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol, 25(3), 487-96 (2005). (Pubitemid 40315668)
118. M. A. Cotter, A. M. Jack and N. E. Cameron: Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond), 103(3), 311-21 (2002). (Pubitemid 35007223)
119. K. Naruse, C. Rask-Madsen, N. Takahara, S. W. Ha, K. Suzuma, K. J. Way, J. R. Jacobs, A. C. Clermont, K. Ueki, Y. Ohshiro, J. Zhang, A. B. Goldfine and G. L. King: Activation of vascular protein kinase C-beta inhibits Aktdependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes, 55(3), 691- 8 (2006). (Pubitemid 43343225)
120. J. A. Beckman, A. B. Goldfine, M. B. Gordon, L. A. Garrett and M. A. Creager: Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res, 90(1), 107-11 (2002). (Pubitemid 34074616)
121. A. Otsuka, K. Azuma, T. Iesaki, F. Sato, T. Hirose, T. Shimizu, Y. Tanaka, H. Daida, R. Kawamori and H. Watada: Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia, 48(12), 2667-74 (2005). (Pubitemid 41738236)
122. R. Piga, Y. Naito, S. Kokura, O. Handa and T. Yoshikawa: Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis, 193(2), 328-34 (2007). (Pubitemid 47058120)
123. N. Ohgami, A. Miyazaki, M. Sakai, A. Kuniyasu, H. Nakayama and S. Horiuchi: Advanced glycation end products (AGE) inhibit scavenger receptor class B type Imediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb, 10(1), 1-6 (2003).
124. J. M. Forbes, L. T. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, M. E. Cooper and T. J. Allen: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes, 53(7), 1813-23 (2004). (Pubitemid 38857040)
125. L. G. Bucciarelli, T. Wendt, W. Qu, Y. Lu, E. Lalla, L. L. Rong, M. T. Goova, B. Moser, T. Kislinger, D. C. Lee, Y. Kashyap, D. M. Stern and A. M. Schmidt: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 106(22), 2827-35 (2002). (Pubitemid 35396983)
126. H. Cai: NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res, 96(8), 818-22 (2005). (Pubitemid 40604964)
127. R. Salvayre, N. Auge, H. Benoist and A. Negre- Salvayre: Oxidized low-density lipoprotein-induced apoptosis. Biochim Biophys Acta, 1585(2-3), 213-21 (2002). (Pubitemid 36092085)
128. K. Brand, T. Eisele, U. Kreusel, M. Page, S. Page, M. Haas, A. Gerling, C. Kaltschmidt, F. J. Neumann, N. Mackman, P. A. Baeurele, A. K. Walli and D. Neumeier: Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol, 17(10), 1901-9 (1997). (Pubitemid 28057088)
129. B. D. Lamon and D. P. Hajjar: Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol, 173(5), 1253-64 (2008).
130. M. P. de Winther, E. Kanters, G. Kraal and M. H. Hofker: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol, 25(5), 904-14 (2005). (Pubitemid 40627833)
131. A. M. Fulton, X. Ma and N. Kundu: Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res, 66(20), 9794-7 (2006). (Pubitemid 44672027)
132. T. Ulven and E. Kostenis: Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem, 6(13), 1427-44 (2006). (Pubitemid 44144925)
133. S. Pavlovic, B. Du, K. Sakamoto, K. M. Khan, C. Natarajan, R. M. Breyer, A. J. Dannenberg and D. J. Falcone: Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem, 281(6), 3321-8 (2006). (Pubitemid 43852881)
134. W. J. Zhang, K. E. Bird, T. S. McMillen, R. C. LeBoeuf, T. M. Hagen and B. Frei: Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation, 117(3), 421-8 (2008).
135. Y. H. Chen, S. J. Lin, Y. L. Chen, P. L. Liu and J. W. Chen: Anti-inflammatory effects of different drugs/agentswith antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets, 6(4), 279-304 (2006).
136. M. Milagros Rocha and V. M. Victor: Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med Sci Monit, 13(7), RA132- 45 (2007).
137. V. M. Victor and M. Rocha: Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des, 13(8), 845-63 (2007). (Pubitemid 46585507)
138. M. Hersberger: Potential role of the lipoxygenase derived lipid mediators in atherosclerosis: leukotrienes, lipoxins and resolvins. Clin Chem Lab Med, 48(8), 1063-73 (2010).
139. L. J. Crofford: COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl, 49, 15-9 (1997).
140. F. Cipollone, G. Cicolini and M. Bucci: Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther, 118(2), 161-80 (2008).
141. M. E. Burleigh, V. R. Babaev, J. A. Oates, R. C. Harris, S. Gautam, D. Riendeau, L. J. Marnett, J. D. Morrow, S. Fazio and M. F. Linton: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation, 105(15), 1816-23 (2002). (Pubitemid 34408892)
142. R. Langenbach, C. Loftin, C. Lee and H. Tiano: Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol, 58(8), 1237-46 (1999). (Pubitemid 29406158)
143. M. Zhang, Y. Dong, J. Xu, Z. Xie, Y. Wu, P. Song, M. Guzman, J. Wu and M. H. Zou: Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res, 102(3), 328-37 (2008). (Pubitemid 351271653)
144. P. Song, M. Zhang, S. Wang, J. Xu, H. C. Choi and M. H. Zou: Thromboxane A2 receptor activates a Rhoassociated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem, 284(25), 17120-8 (2009).
145. M. Zhang, P. Song, J. Xu and M. H. Zou: Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol, 31(1), 125-32 (2011).
146. M. Mehrabian, J. Wong, X. Wang, Z. Jiang, W. Shi, A. M. Fogelman and A. J. Lusis: Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res, 89(2), 125-30 (2001). (Pubitemid 34135819)
147. L. Zhao, M. P. Moos, R. Grabner, F. Pedrono, J. Fan, B. Kaiser, N. John, S. Schmidt, R. Spanbroek, K. Lotzer, L. Huang, J. Cui, D. J. Rader, J. F. Evans, A. J. Habenicht and C. D. Funk: The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med, 10(9), 966-73 (2004). (Pubitemid 39273738)
148. H. Qiu, A. Gabrielsen, H. E. Agardh, M. Wan, A. Wetterholm, C. H. Wong, U. Hedin, J. Swedenborg, G. K. Hansson, B. Samuelsson, G. Paulsson-Berne and J. Z. Haeggstrom: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA, 103(21), 8161-6 (2006). (Pubitemid 43801069)
149. K. W. Seo, S. J. Lee, C. E. Kim, M. R. Yun, H. M. Park, J. W. Yun, S. S. Bae and C. D. Kim: Participation of 5-lipoxygenase-derived LTB(4) in 4-hydroxynonenalenhanced MMP-2 production in vascular smooth muscle cells. Atherosclerosis, 208(1), 56-61 (2010).
150. A. Aljada, H. Ghanim, R. Saadeh and P. Dandona: Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab, 86(1), 450-3 (2001). (Pubitemid 32109834)
151. G. Zeng and M. J. Quon: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest, 98(4), 894-8 (1996). (Pubitemid 26293305)
152. A. Aljada and P. Dandona: Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism, 49(2), 147-50 (2000). (Pubitemid 30090874)
153. P. Dandona, A. Aljada and P. Mohanty: The antiinflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia, 45(6), 924-30 (2002).
154. J. F. Woessner Jr.: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5(8), 2145-54 (1991). (Pubitemid 21905847)
155. Z. S. Galis, G. K. Sukhova, M. W. Lark and P. Libby: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 94(6), 2493-503 (1994) doi:10.1172/JCI117619. (Pubitemid 24379627)
156. F. Fath-Ordoubadi and K. J. Beatt: Glucose-insulinpotassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation, 96(4), 1152-6 (1997). (Pubitemid 27344217)
157. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 310(6972), 83-8 (1995).
158. B. B. Zhang, G. Zhou and C. Li: AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab, 9(5), 407-16 (2009).
159. D. Sag, D. Carling, R. D. Stout and J. Suttles: Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol, 181(12), 8633-41 (2008).
160. J. M. Cacicedo, N. Yagihashi, J. F. Keaney Jr., N. B. Ruderman and Y. Ido: AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun, 324(4), 1204-9 (2004). (Pubitemid 40292150)
161. G. Pilon, P. Dallaire and A. Marette: Inhibition of inducible nitric-oxide synthase by activators of AMPactivated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem, 279(20), 20767-74 (2004). (Pubitemid 38656473)
162. S. Giri, N. Nath, B. Smith, B. Viollet, A. K. Singh and I. Singh: 5-aminoimidazole-4-carboxamide-1-beta-4- ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci, 24(2), 479-87 (2004). (Pubitemid 38112379)
163. Y. Hattori, K. Suzuki, S. Hattori and K. Kasai: Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 47(6), 1183-8 (2006). (Pubitemid 44289177)
164. Z. Xie, J. Zhang, J. Wu, B. Viollet and M. H. Zou: Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes, 57(12), 3222-30 (2008).
165. H. C. Choi, P. Song, Z. Xie, Y. Wu, J. Xu, M. Zhang, Y. Dong, S. Wang, K. Lau and M. H. Zou: Reactive nitrogen species is required for the activation of the AMPactivated protein kinase by statin in vivo. J Biol Chem, 283(29), 20186-97 (2008).
166. Y. Dong, M. Zhang, B. Liang, Z. Xie, Z. Zhao, S. Asfa, H. C. Choi and M. H. Zou: Reduction of AMPactivated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation, 121(6), 792-803 (2010).
167. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk- Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear and D. E. Moller: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108(8), 1167-74 (2001). (Pubitemid 32995375)
168. B. Molavi, N. Rassouli, S. Bagwe and N. Rasouli: A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag, 3(6), 967-73 (2007).
169. P. Rosen and N. F. Wiernsperger: Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev, 22(4), 323-30 (2006). (Pubitemid 44070509)
170. D. Bonnefont-Rousselot, B. Raji, S. Walrand, M. Gardes-Albert, D. Jore, A. Legrand, J. Peynet and M. P. Vasson: An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism, 52(5), 586-9 (2003). (Pubitemid 36896285)
171. N. Ouslimani, J. Peynet, D. Bonnefont-Rousselot, P. Therond, A. Legrand and J. L. Beaudeux: Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism, 54(6), 829- 34 (2005). (Pubitemid 40725333)
172. L. Li, J. C. Mamputu, N. Wiernsperger and G. Renier: Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes, 54(7), 2227-34 (2005). (Pubitemid 40911288)
173. S. S. Lund, L. Tarnow, C. D. Stehouwer, C. G. Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U. M. Smidt, O. Pedersen, H. H. Parving and A. A. Vaag: Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol, 158(5), 631-41 (2008). (Pubitemid 351639600)
174. A. Yessoufou and W. Wahli: Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly, 140, w13071 (2010).
175. B. P. Kota, T. H. Huang and B. D. Roufogalis: An overview on biological mechanisms of PPARs. Pharmacol Res, 51(2), 85-94 (2005). (Pubitemid 40040538)
176. A. Yessoufou, A. Hichami, P. Besnard, K. Moutairou and N. A. Khan: Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: Modulation of T cell differentiation. Endocrinology, 147(9), 4410-8 (2006). (Pubitemid 44268392)
177. P. Delerive, K. De Bosscher, S. Besnard, W. Vanden Berghe, J. M. Peters, F. J. Gonzalez, J. C. Fruchart, A. Tedgui, G. Haegeman and B. Staels: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. J Biol Chem, 274(45), 32048-54 (1999).
178. M. Adachi, R. Kurotani, K. Morimura, Y. Shah, M. Sanford, B. B. Madison, D. L. Gumucio, H. E. Marin, J. M. Peters, H. A. Young and F. J. Gonzalez: Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut, 55(8), 1104-13 (2006). (Pubitemid 44085676)
179. Y. M. Shah, K. Morimura and F. J. Gonzalez: Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol, 292(2), G657-66 (2007).
180. D. S. Straus and C. K. Glass: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol, 28(12), 551-8 (2007). (Pubitemid 350101420)
181. M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L. J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki and R. A. DeFronzo: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes, 52(6), 1364-70 (2003). (Pubitemid 36666189)
182. N. Rasouli, U. Raue, L. M. Miles, T. Lu, G. B. Di Gregorio, S. C. Elbein and P. A. Kern: Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab, 288(5), E930-4 (2005). (Pubitemid 40547887)
183. A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern and R. J. Owens: Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab, 291(5), E1100-5 (2006).
184. N. F. Chu, M. H. Shen, D. M. Wu and S. M. Shieh: Plasma TNF-R1 and insulin concentrations in relation to leptin levels among normal and overweight children. Clin Biochem, 35(4), 287-92 (2002).
185. H. Yki-Jarvinen: Thiazolidinediones. N Engl J Med, 351(11), 1106-18 (2004).
186. N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein and P. A. Kern: Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab, 290(1), E42-E46 (2006).
187. J. Hwang, D. J. Kleinhenz, H. L. Rupnow, A. G. Campbell, P. M. Thule, R. L. Sutliff and C. M. Hart: The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul Pharmacol, 46(6), 456-62 (2007). (Pubitemid 46552287)
188. P. M. Ridker, C. P. Cannon, D. Morrow, N. Rifai, L. M. Rose, C. H. McCabe, M. A. Pfeffer and E. Braunwald: C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 352(1), 20-8 (2005). (Pubitemid 40075677)
189. D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. D. Wiviott, M. A. Blazing, A. Shui, N. Rifai, R. M. Califf and E. Braunwald: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation, 114(4), 281-8 (2006). (Pubitemid 44297094)
190. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen, T. Crowe, W. J. Sasiela, J. Tsai, J. Orazem, R. D. Magorien, C. O'Shaughnessy and P. Ganz: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 352(1), 29-38 (2005). (Pubitemid 40075678)
191. G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, A. Montinaro and G. Di Sciascio: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 49(12), 1272-8 (2007). (Pubitemid 46467240)
192. Y. Asanuma, A. Oeser, A. K. Shintani, E. Turner, N. Olsen, S. Fazio, M. F. Linton, P. Raggi and C. M. Stein: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med, 349(25), 2407-15 (2003). (Pubitemid 37542989)
193. H. K. Choi and G. Curhan: Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 116(8), 894-900 (2007). (Pubitemid 47300913)
194. J. M. Gelfand, A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis and A. B. Troxel: Risk of myocardial infarction in patients with psoriasis. JAMA, 296(14), 1735-41 (2006). (Pubitemid 44547793)
195. H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman and S. E. Gabriel: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum, 52(3), 722-32 (2005). (Pubitemid 40365093)
196. C. A. Dinarello: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol, 27, 519-50 (2009).
197. P. M. Ridker, N. Rifai, M. Pfeffer, F. Sacks, S. Lepage and E. Braunwald: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 101(18), 2149-53 (2000). (Pubitemid 30253042)
198. C. Heeschen, S. Dimmeler, C. W. Hamm, M. J. van den Brand, E. Boersma, A. M. Zeiher and M. L. Simoons: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med, 348(12), 1104-11 (2003). (Pubitemid 36337321)
199. K. Otterdal, C. Smith, E. Oie, T. M. Pedersen, A. Yndestad, E. Stang, K. Endresen, N. O. Solum, P. Aukrust and J. K. Damas: Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood, 108(3), 928-35 (2006). (Pubitemid 44154627)
200. W. J. Sandberg, A. Yndestad, E. Oie, C. Smith, T. Ueland, O. Ovchinnikova, A. K. Robertson, F. Muller, A. G. Semb, H. Scholz, A. K. Andreassen, L. Gullestad, J. K. Damas, S. S. Froland, G. K. Hansson, B. Halvorsen and P. Aukrust: Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol, 26(4), 857- 63 (2006). (Pubitemid 43732163)
201. T. Omland, T. Ueland, A. M. Jansson, A. Persson, T. Karlsson, C. Smith, J. Herlitz, P. Aukrust, M. Hartford and K. Caidahl: Circulating osteoprotegerin levels and longterm prognosis in patients with acute coronary syndromes. J Am Coll Cardiol, 51(6), 627-33 (2008). (Pubitemid 351193104)
202. P. Secchiero, F. Corallini, C. Ceconi, G. Parrinello, S. Volpato, R. Ferrari and G. Zauli: Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One, 4(2), e4442 (2009).
203. T. Waehre, A. Yndestad, C. Smith, T. Haug, S. H. Tunheim, L. Gullestad, S. S. Froland, A. G. Semb, P. Aukrust and J. K. Damas: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation, 109(16), 1966-72 (2004). (Pubitemid 38544487)
204. Z. Mallat, P. Henry, R. Fressonnet, S. Alouani, A. Scoazec, P. Beaufils, Y. Chvatchko and A. Tedgui: Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart, 88(5), 467-9 (2002). (Pubitemid 35221955)
205. M. Shimpo, D. A. Morrow, E. O. Weinberg, M. S. Sabatine, S. A. Murphy, E. M. Antman and R. T. Lee: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 109(18), 2186-90 (2004). (Pubitemid 38625395)
206. S. Jovinge, A. Hamsten, P. Tornvall, A. Proudler, P. Bavenholm, C. G. Ericsson, I. Godsland, U. de Faire and J. Nilsson: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism, 47(1), 113-8 (1998). (Pubitemid 28086243)
207. J. Nilsson, E. Bengtsson, G. N. Fredrikson and H. Bjorkbacka: Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol, 19(5), 519-24 (2008).
208. W. Palinski and J. L. Witztum: Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med, 247(3), 371-80 (2000). (Pubitemid 30180039)
209. J. A. Berliner, M. Navab, A. M. Fogelman, J. S. Frank, L. L. Demer, P. A. Edwards, A. D. Watson and A. J. Lusis: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation, 91(9), 2488-96 (1995).
210. S. Horkko, C. J. Binder, P. X. Shaw, M. K. Chang, G. Silverman, W. Palinski and J. L. Witztum: Immunological responses to oxidized LDL. Free Radic Biol Med, 28(12), 1771-9 (2000). (Pubitemid 30628664)
211. R. Roberts, V. DeMello and B. E. Sobel: Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation, 53(3 Suppl), I204-6 (1976).
212. D. M. Yellon and D. J. Hausenloy: Myocardial reperfusion injury. N Engl J Med, 357(11), 1121-35 (2007).
213. R. Klingenberg and G. K. Hansson: Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J, 30(23), 2838-44 (2009).